tirozinkinázgátlókat

Tirozinkinázgátlók, or tyrosine kinase inhibitors (TKIs), are a class of drugs used in cancer therapy. They work by targeting specific proteins called tyrosine kinases, which are often overactive in cancer cells and promote their growth and division. By blocking the action of these kinases, TKIs can slow down or stop cancer progression.

These drugs are a significant advancement in targeted therapy. Instead of broadly affecting all rapidly dividing cells, as traditional chemotherapy does, TKIs focus on the molecular abnormalities driving a particular cancer. This targeted approach can lead to fewer side effects and improved treatment outcomes for certain types of cancer.

TKIs are typically administered orally, often as pills. Their development has been a result of extensive research into the genetic and molecular pathways involved in cancer development. Different TKIs target different specific tyrosine kinases, making them effective against a variety of cancers, including chronic myeloid leukemia (CML), certain types of lung cancer, and gastrointestinal stromal tumors (GIST).

While TKIs have revolutionized cancer treatment for many, they are not universally effective. Their success depends on the presence of the specific tyrosine kinase mutation or overactivation in the tumor. Resistance to TKIs can also develop over time, requiring adjustments in treatment. Ongoing research aims to develop new TKIs and strategies to overcome resistance.